marketcaparena
Search

    PGEN

    PRECIGEN, INC.

    Company overview

    Market capitalization
    $2.80B
    Employees
    160
    Latest publication
    2026-09-29
    About PRECIGEN, INC.

    Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue23,252,000USD4,565,000USD2,922,000USD856,000USD1,341,000USD1,190,000USD953,000USD717,000USD
    Cost Of Revenue2,877,000USD1,914,000USD1,353,000USD1,555,000USD1,419,000USD1,169,000USD1,009,000USD1,014,000USD
    Gross Profit20,375,000USD2,651,000USD1,569,000USD-699,000USD-78,000USD21,000USD-56,000USD-297,000USD
    Research Development5,320,000USD6,672,000USD12,059,000USD11,488,000USD10,159,000USD11,758,000USD11,370,000USD15,693,000USD
    Selling General Administrative21,049,000USD17,645,000USD23,991,000USD16,133,000USD12,359,000USD11,000,000USD9,836,000USD10,306,000USD
    Total Operating Expenses26,369,000USD24,317,000USD36,050,000USD31,065,000USD22,518,000USD28,537,000USD21,206,000USD60,544,000USD
    Operating Income-5,994,000USD-21,666,000USD-34,481,000USD-31,764,000USD-22,596,000USD-28,516,000USD-21,262,000USD-60,841,000USD
    Interest Income683,000USD1,067,000USD534,000USD696,000USD918,000USD208,000USD283,000USD319,000USD
    Interest Expense2,908,000USD2,964,000USD902,000USD0USD1,000USD6,000USD2,000USD2,000USD
    Net Interest Income-2,225,000USD-1,897,000USD-368,000USD696,000USD917,000USD208,000USD281,000USD317,000USD
    Income Before Tax-7,929,000USD-23,503,000USD-146,344,000USD-26,639,000USD-54,153,000USD-19,814,000USD-23,966,000USD-60,481,000USD
    Tax Provision0USD0USD0USD3,000USD0USD-87,000USD12,000USD-1,689,000USD
    Net Income-7,929,000USD-23,503,000USD-146,344,000USD-26,642,000USD-54,153,000USD-19,727,000USD-23,978,000USD-58,792,000USD
    Net Income From Continuing Ops-7,929,000USD-23,503,000USD-146,344,000USD-26,642,000USD-54,153,000USD-19,727,000USD-23,978,000USD-58,792,000USD
    Ebit-5,994,000USD-21,666,000USD-34,481,000USD-27,857,000USD-22,596,000USD-19,814,000USD-23,964,000USD-60,479,000USD
    Ebitda-4,895,000USD-20,529,000USD-33,678,000USD-27,227,000USD-21,967,000USD-19,153,000USD-23,290,000USD-58,883,000USD
    Depreciation And Amortization1,099,000USD1,137,000USD803,000USD630,000USD629,000USD661,000USD674,000USD1,596,000USD
    Reconciled Depreciation1,099,000USD1,137,000USD803,000USD630,000USD629,000USD661,000USD674,000USD1,596,000USD
    Total Other Income Expense Net-1,935,000USD-1,837,000USD-111,863,000USD5,125,000USD-31,557,000USD8,702,000USD-2,704,000USD360,000USD
    Income Tax Expense—6,000USD179,000,000USD3,000USD-87,000USD-87,000USD12,000USD-1,689,000USD
    Unclassified Operating Expenses———3,444,000USD—5,779,000USD—34,545,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue9,684,000USD3,925,000USD6,225,000USD26,909,000USD14,267,000USD31,992,000USD31,992,000USD160,574,000USD
    Cost Of Revenue6,096,000USD4,267,000USD6,119,000USD6,339,000USD53,678,000USD44,802,000USD5,374,000USD63,287,000USD
    Gross Profit3,588,000USD-342,000USD106,000USD20,570,000USD-39,411,000USD-12,810,000USD26,618,000USD97,287,000USD
    Research Development40,060,000USD53,070,000USD48,614,000USD47,170,000USD47,933,000USD39,428,000USD39,428,000USD404,586,000USD
    Selling General Administrative70,128,000USD41,293,000USD40,415,000USD48,006,000USD74,122,000USD91,704,000USD100,844,000USD137,807,000USD
    Total Operating Expenses110,188,000USD134,687,000USD99,864,000USD96,296,000USD52,537,000USD73,508,000USD112,936,000USD542,393,000USD
    Operating Income-106,600,000USD-135,029,000USD-99,758,000USD-75,726,000USD-91,948,000USD-86,318,000USD-86,318,000USD-505,610,000USD
    Interest Income3,215,000USD1,418,000USD3,237,000USD133,000USD1,617,000USD2,451,000USD3,871,000USD19,084,000USD
    Interest Expense3,867,000USD6,000USD468,000USD6,774,000USD18,755,000USD18,400,000USD18,209,000USD8,530,000USD
    Net Interest Income-652,000USD1,412,000USD2,769,000USD-6,641,000USD-17,274,000USD-15,949,000USD-13,795,000USD10,554,000USD
    Income Before Tax-250,639,000USD-128,028,000USD-96,362,000USD-79,966,000USD-110,967,000USD-104,524,000USD-104,524,000USD-536,234,000USD
    Income Tax Expense3,000USD-1,793,000USD-458,000USD-189,000USD-160,000USD-82,000USD-82,000USD-21,528,000USD
    Tax Provision3,000USD-1,793,000USD-458,000USD-189,000USD-160,000USD-82,000USD-930,000USD-21,528,000USD
    Net Income-250,642,000USD-126,235,000USD-95,904,000USD28,317,000USD-92,166,000USD-170,521,000USD-170,521,000USD-509,336,000USD
    Net Income From Continuing Ops-250,642,000USD-126,235,000USD-95,904,000USD-79,777,000USD-96,765,000USD-103,773,000USD-207,757,000USD-514,706,000USD
    Ebit-106,600,000USD-128,022,000USD-95,894,000USD-73,192,000USD-91,405,000USD-85,504,000USD-86,315,000USD-373,160,000USD
    Ebitda-103,401,000USD-123,496,000USD-89,226,000USD-62,427,000USD-77,644,000USD-67,988,000USD-68,799,000USD-349,055,000USD
    Depreciation And Amortization3,199,000USD4,526,000USD6,668,000USD10,765,000USD13,761,000USD17,516,000USD17,516,000USD24,105,000USD
    Reconciled Depreciation3,199,000USD4,526,000USD6,668,000USD10,765,000USD13,761,000USD17,516,000USD24,896,000USD33,112,000USD
    Total Other Income Expense Net-144,039,000USD7,001,000USD3,396,000USD-4,240,000USD-19,019,000USD-18,206,000USD-18,206,000USD-26,245,000USD
    Unclassified Operating Expenses—40,324,000USD10,835,000USD1,120,000USD-69,518,000USD-57,624,000USD-27,336,000USD—
    Non Operating Income Net Other———2,534,000USD1,284,000USD1,004,000USD8,419,000USD-22,094,000USD
    Discontinued Operations———108,094,000USD4,599,000USD-66,748,000USD-116,159,000USD-100,389,000USD
    Net Income Applicable To Common Shares———28,317,000USD-92,166,000USD-170,521,000USD-322,324,000USD-509,336,000USD
    Minority Interest————0USD0USD-1,592,000USD-5,370,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Assets138,627,000USD156,621,000USD171,264,000USD101,896,000USD128,787,000USD145,266,000USD83,474,000USD73,160,000USD
    Intangible Assets2,864,000USD3,182,000USD3,500,000USD3,818,000USD4,136,000USD4,455,000USD4,773,000USD5,091,000USD
    Other Current Assets3,996,000USD3,434,000USD4,303,000USD2,431,000USD3,295,000USD3,341,000USD5,153,000USD3,163,000USD
    Total Liab118,392,000USD135,710,000USD129,396,000USD138,675,000USD142,847,000USD106,753,000USD28,098,000USD29,990,000USD
    Total Stockholder Equity20,235,000USD20,911,000USD41,868,000USD-36,779,000USD-14,060,000USD38,513,000USD55,376,000USD43,170,000USD
    Other Current Liab17,037,000USD24,185,000USD24,204,000USD17,928,000USD19,402,000USD16,442,000USD15,501,000USD16,530,000USD
    Capital Stock0USD0USD0USD0USD0USD0USD0USD0USD
    Retained Earnings-2,349,277,000USD-2,341,348,000USD-2,317,845,000USD-2,171,501,000USD-2,144,859,000USD-2,090,706,000USD-2,070,979,000USD-2,047,001,000USD
    Good Will15,232,000USD15,232,000USD15,232,000USD15,232,000USD19,139,000USD19,139,000USD24,918,000USD24,918,000USD
    Cash7,480,000USD30,234,000USD14,322,000USD13,760,000USD6,058,000USD29,517,000USD24,725,000USD9,345,000USD
    Cash And Short Term Investments56,246,000USD97,858,000USD121,135,000USD59,753,000USD80,242,000USD97,910,000USD28,631,000USD19,536,000USD
    Total Current Assets101,672,000USD115,235,000USD129,597,000USD62,755,000USD84,601,000USD102,414,000USD34,513,000USD23,715,000USD
    Total Current Liabilities21,104,000USD37,306,000USD32,069,000USD23,193,000USD23,986,000USD21,518,000USD21,216,000USD23,023,000USD
    Current Deferred Revenue410,000USD517,000USD480,000USD413,000USD549,000USD589,000USD407,000USD378,000USD
    Net Debt90,770,000USD-25,118,000USD83,870,000USD-8,607,000USD-641,000USD-24,015,000USD-18,976,000USD-3,004,000USD
    Short Term Debt1,068,000USD1,136,000USD1,123,000USD930,000USD928,000USD956,000USD988,000USD1,269,000USD
    Short Long Term Debt Total98,250,000USD5,116,000USD98,192,000USD5,153,000USD5,417,000USD5,502,000USD5,749,000USD6,341,000USD
    Long Term Debt93,519,000USD93,174,000USD92,890,000USD—————
    Long Term Investments489,000USD2,511,000USD2,508,000USD—750,000USD0USD——
    Short Term Investments48,766,000USD67,624,000USD106,813,000USD45,993,000USD74,184,000USD68,393,000USD3,906,000USD10,191,000USD
    Net Receivables26,705,000USD4,362,000USD1,100,000USD571,000USD1,064,000USD1,163,000USD729,000USD1,016,000USD
    Inventory14,725,000USD9,581,000USD3,059,000USD——0USD——
    Accounts Payable2,589,000USD11,985,000USD6,262,000USD3,922,000USD3,107,000USD3,531,000USD4,320,000USD4,846,000USD
    Property Plant Equipment Net17,588,000USD18,437,000USD19,595,000USD19,429,000USD19,644,000USD18,799,000USD18,753,000USD18,918,000USD
    Property Plant Equipment Gross42,120,000USD42,186,000USD42,601,000USD41,944,000USD42,824,000USD41,670,000USD41,284,000USD41,147,000USD
    Accumulated Other Comprehensive Income-17,000USD7,000USD24,000USD11,000USD12,000USD12,000USD13,000USD-2,909,000USD
    Common Stock Shares Outstanding312,980,562shares312,980,562shares296,434,726shares296,434,726shares293,880,000shares292,869,097shares275,881,170shares252,366,533shares
    Non Current Assets Total36,955,000USD41,386,000USD41,667,000USD39,141,000USD44,186,000USD42,852,000USD48,961,000USD49,445,000USD
    Non Current Liabilities Total97,288,000USD98,404,000USD97,327,000USD115,482,000USD118,861,000USD85,235,000USD6,882,000USD6,967,000USD
    Non Current Liabilities Other106,000USD134,000USD163,000USD—————
    Non Currrent Assets Other782,000USD908,000USD832,000USD662,000USD517,000USD459,000USD517,000USD518,000USD
    Net Working Capital80,568,000USD77,929,000USD97,528,000USD39,562,000USD60,615,000USD80,896,000USD13,297,000USD692,000USD
    Unclassified Non Current Liabilities3,663,000USD5,096,000USD4,274,000USD115,482,000USD118,861,000USD85,235,000USD6,882,000USD6,967,000USD
    Unclassified Equity2,369,529,000USD2,362,252,000USD2,359,689,000USD2,134,711,000USD2,130,787,000USD2,129,207,000USD2,126,342,000USD2,093,080,000USD
    Unclassified Non Current Assets—1,116,000USD——-1,271,000USD———
    Other Assets————1,271,000USD——1USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets156,621,000USD145,266,000USD151,043,000USD215,977,000USD359,856,000USD314,587,000USD455,763,000USD716,177,000USD
    Intangible Assets3,182,000USD4,455,000USD40,701,000USD44,455,000USD52,291,000USD65,396,000USD68,346,000USD129,291,000USD
    Other Current Assets3,434,000USD3,341,000USD4,325,000USD48,118,000USD45,659,000USD17,045,000USD117,271,000USD21,469,000USD
    Total Liab135,710,000USD106,753,000USD32,545,000USD89,718,000USD252,508,000USD247,413,000USD384,052,000USD337,455,000USD
    Total Stockholder Equity20,911,000USD38,513,000USD118,498,000USD126,259,000USD107,348,000USD67,174,000USD71,711,000USD362,855,000USD
    Other Current Liab24,185,000USD16,442,000USD19,548,000USD30,124,000USD28,598,000USD31,712,000USD75,461,000USD37,556,000USD
    Capital Stock0USD0USD0USD0USD0USD0USD0USD0USD
    Retained Earnings-2,341,348,000USD-2,090,706,000USD-1,964,471,000USD-1,868,567,000USD-1,915,556,000USD-1,823,390,000USD-1,652,869,000USD-1,330,545,000USD
    Good Will15,232,000USD19,139,000USD26,612,000USD36,923,000USD37,554,000USD54,363,000USD63,754,000USD149,585,000USD
    Cash30,234,000USD29,517,000USD7,578,000USD4,858,000USD36,423,000USD51,792,000USD65,793,000USD102,768,000USD
    Cash And Short Term Investments97,858,000USD97,910,000USD62,855,000USD55,950,000USD108,663,000USD100,117,000USD75,053,000USD222,840,000USD
    Total Current Assets115,235,000USD102,414,000USD68,755,000USD118,159,000USD156,628,000USD148,948,000USD234,643,000USD285,483,000USD
    Total Current Liabilities37,306,000USD21,518,000USD22,985,000USD78,645,000USD34,645,000USD42,127,000USD122,912,000USD61,562,000USD
    Current Deferred Revenue517,000USD589,000USD509,000USD25,000USD1,490,000USD2,800,000USD5,697,000USD15,554,000USD
    Net Debt-25,118,000USD-24,015,000USD-481,000USD46,562,000USD153,651,000USD130,491,000USD166,873,000USD109,492,000USD
    Short Term Debt1,136,000USD956,000USD1,202,000USD44,428,000USD1,445,000USD3,017,000USD36,226,000USD945,000USD
    Short Long Term Debt Total5,116,000USD5,502,000USD7,097,000USD51,420,000USD190,074,000USD182,283,000USD232,666,000USD212,260,000USD
    Long Term Debt93,174,000USD———182,749,000USD171,522,000USD186,321,000USD211,235,000USD
    Long Term Investments2,511,000USD0USD—0USD48,562,000USD0USD1,461,000USD18,859,000USD
    Short Term Investments67,624,000USD68,393,000USD55,277,000USD51,092,000USD72,240,000USD48,325,000USD9,260,000USD120,072,000USD
    Net Receivables4,362,000USD1,163,000USD1,575,000USD13,804,000USD1,980,000USD20,427,000USD26,222,000USD26,565,000USD
    Inventory9,581,000USD0USD1USD287,000USD326,000USD11,359,000USD16,097,000USD21,447,000USD
    Accounts Payable11,985,000USD3,531,000USD1,726,000USD4,068,000USD3,112,000USD4,598,000USD5,528,000USD11,973,000USD
    Property Plant Equipment Net18,437,000USD18,799,000USD14,129,000USD15,292,000USD18,553,000USD44,277,000USD86,197,000USD128,874,000USD
    Property Plant Equipment Gross42,186,000USD41,670,000USD38,412,000USD7,329,000USD34,315,000USD43,409,000USD86,197,000USD—
    Accumulated Other Comprehensive Income7,000USD12,000USD-1,947,000USD-3,488,000USD203,000USD3,997,000USD-27,468,000USD-28,612,000USD
    Common Stock Shares Outstanding304,707,644shares267,727,000shares244,536,221shares200,360,821shares197,759,900shares167,065,539shares154,138,774shares129,521,731shares
    Non Current Assets Total41,386,000USD42,852,000USD82,288,000USD97,818,000USD203,228,000USD165,639,000USD221,120,000USD430,694,000USD
    Non Current Liabilities Total98,404,000USD85,235,000USD9,560,000USD11,073,000USD217,863,000USD205,286,000USD261,140,000USD275,893,000USD
    Non Current Liabilities Other134,000USD———32,575,000USD30,867,000USD71,985,000USD57,445,000USD
    Non Currrent Assets Other908,000USD459,000USD846,000USD-8,423,000USD46,268,000USD-8,115,000USD-13,882,000USD-6,333,000USD
    Net Working Capital77,929,000USD80,896,000USD45,770,000USD39,514,000USD121,983,000USD106,821,000USD111,731,000USD223,921,000USD
    Unclassified Non Current Assets1,116,000USD-68,393,000USD———-9,353,000USD—-154,034,000USD
    Unclassified Non Current Liabilities5,096,000USD85,235,000USD9,560,000USD6,992,000USD-25,612,000USD-26,020,000USD-50,970,000USD-64,677,000USD
    Unclassified Equity2,362,252,000USD2,129,207,000USD2,084,916,000USD1,998,314,000USD2,022,701,000USD1,886,567,000USD1,752,048,000USD1,722,591,000USD
    Other Assets—68,393,000USD—1,025,000USD1,188,000USD10,956,000USD1,362,000USD158,119,000USD
    Other Liab———4,081,000USD25,612,000USD26,020,000USD50,970,000USD64,677,000USD
    Short Long Term Debt———43,219,000USD402,000USD360,000USD33,592,000USD1,025,000USD
    Net Tangible Assets———126,259,000USD-915,000USD-52,585,000USD-60,389,000USD83,979,000USD
    Unclassified Current Liabilities———-43,219,000USD——-33,592,000USD-5,491,000USD
    Deferred Long Term Liab————2,539,000USD2,897,000USD2,834,000USD7,213,000USD
    Common Stock———————-579,000USD
    Unclassified Current Assets———————-6,838,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-7,929,000USD-23,503,000USD-146,344,000USD-26,642,000USD-54,153,000USD-19,727,000USD-23,978,000USD-58,792,000USD
    Depreciation1,099,000USD1,137,000USD803,000USD630,000USD629,000USD661,000USD674,000USD1,596,000USD
    Stock Based Compensation3,006,000USD2,163,000USD4,388,000USD1,638,000USD2,677,000USD2,865,000USD2,061,000USD1,964,000USD
    Other Non Cash Items502,000USD-429,000USD111,256,000USD-1,007,000USD32,302,000USD5,920,000USD2,779,000USD32,510,000USD
    Change To Account Receivables-22,343,000USD-3,262,000USD-532,000USD496,000USD99,000USD-440,000USD-27,000USD468,000USD
    Change To Inventory-4,879,000USD-6,261,000USD-2,948,000USD—0USD———
    Change In Working Capital-40,505,000USD-2,828,000USD828,000USD6,404,000USD2,220,000USD2,127,000USD-4,281,000USD1,304,000USD
    Total Cash From Operating Activities-43,827,000USD-23,460,000USD-29,069,000USD-18,977,000USD-16,325,000USD-8,243,000USD-22,733,000USD-23,107,000USD
    Capital Expenditures-258,000USD-622,000USD-389,000USD-966,000USD-622,000USD-1,028,000USD-882,000USD-2,323,000USD
    Free Cash Flow-44,085,000USD-24,082,000USD-29,458,000USD-19,943,000USD-16,947,000USD-9,271,000USD-23,615,000USD-25,430,000USD
    Investments21,225,000USD39,884,000USD-63,386,000USD28,442,000USD-6,457,000USD-65,367,000USD5,653,000USD14,955,000USD
    Total Cashflows From Investing Activities20,967,000USD39,866,000USD-63,386,000USD28,442,000USD-6,457,000USD-65,367,000USD5,653,000USD14,955,000USD
    Total Cash From Financing Activities109,000USD-514,000USD93,007,000USD-1,766,000USD-679,000USD78,404,000USD32,127,000USD52,000USD
    Sale Purchase Of Stock0USD-355,000USD-1,304,000USD355,000USD-355,000USD—0USD0USD
    Change In Cash-22,754,000USD15,912,000USD562,000USD7,702,000USD-23,459,000USD4,792,000USD15,117,000USD-8,135,000USD
    Begin Period Cash Flow30,234,000USD14,322,000USD13,760,000USD6,058,000USD29,517,000USD24,725,000USD9,608,000USD17,743,000USD
    End Period Cash Flow7,480,000USD30,234,000USD14,322,000USD13,760,000USD6,058,000USD29,517,000USD24,725,000USD9,608,000USD
    Other Cashflows From Financing Activities-146,000USD-3,124,000USD-1,304,000USD-1,302,000USD-324,000USD79,000,000USD294,000USD52,000USD
    Net Borrowings—-654,000USD———0USD0USD—
    Other Cashflows From Investing Activities—46,323,000USD——3,000USD—57,000USD—
    Unclassified Investing Cash Flow—-45,719,000USD———1,028,000USD—2,323,000USD
    Unclassified Financing Cash Flow—3,619,000USD95,615,000USD——-79,000,000USD31,833,000USD—
    Issuance Of Capital Stock—————78,404,000USD31,833,000USD0USD
    Unclassified Operating Cash Flow———————-1,689,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-250,642,000USD-126,235,000USD-95,904,000USD28,317,000USD-92,166,000USD-170,521,000USD-170,521,000USD-514,706,000USD
    Depreciation3,199,000USD4,526,000USD6,668,000USD10,765,000USD13,761,000USD17,516,000USD17,516,000USD33,112,000USD
    Stock Based Compensation10,866,000USD9,471,000USD9,888,000USD10,206,000USD13,904,000USD18,366,000USD18,366,000USD46,991,000USD
    Other Non Cash Items142,122,000USD41,337,000USD-4,174,000USD-78,484,000USD9,701,000USD78,425,000USD78,425,000USD351,626,000USD
    Change To Account Receivables-3,199,000USD414,000USD12,229,000USD-13,513,000USD-6,560,000USD4,325,000USD4,325,000USD-2,698,000USD
    Change To Inventory-9,209,000USD0USD0USD2,341,000USD-1,903,000USD2,511,000USD2,511,000USD-478,000USD
    Change In Working Capital6,624,000USD4,523,000USD17,071,000USD-35,699,000USD-804,000USD-20,651,000USD-20,651,000USD-19,985,000USD
    Total Cash From Operating Activities-87,831,000USD-68,173,000USD-66,930,000USD-65,045,000USD-55,771,000USD-77,021,000USD-77,021,000USD-124,240,000USD
    Capital Expenditures-1,995,000USD-8,584,000USD-1,536,000USD-4,924,000USD-7,247,000USD-7,527,000USD-7,527,000USD-41,587,000USD
    Free Cash Flow-89,826,000USD-76,757,000USD-68,466,000USD-69,969,000USD-63,018,000USD-84,548,000USD-84,548,000USD-165,827,000USD
    Investments460,000USD-20,714,000USD-3,087,000USD68,441,000USD-74,053,000USD-35,418,000USD131,290,000USD-126,473,000USD
    Total Cashflows From Investing Activities-1,535,000USD-20,714,000USD-3,087,000USD226,417,000USD-74,540,000USD27,779,000USD27,779,000USD-151,213,000USD
    Net Borrowings92,818,000USD0USD-43,219,000USD-155,293,000USD-466,000USD-2,412,000USD1,214,000USD219,469,000USD
    Total Cash From Financing Activities90,048,000USD110,583,000USD29,589,000USD-155,292,000USD121,187,000USD32,705,000USD32,705,000USD309,795,000USD
    Sale Purchase Of Stock-2,196,000USD0USD0USD1,000USD608,000USD35,117,000USD313,000USD2,336,000USD
    Change In Cash717,000USD21,669,000USD-40,748,000USD5,253,000USD-8,907,000USD-16,184,000USD-16,184,000USD34,637,000USD
    Begin Period Cash Flow29,517,000USD7,848,000USD48,596,000USD43,343,000USD52,250,000USD68,434,000USD68,434,000USD75,545,000USD
    End Period Cash Flow30,234,000USD29,517,000USD7,848,000USD48,596,000USD43,343,000USD52,250,000USD52,250,000USD110,182,000USD
    Other Cashflows From Investing Activities-1,535,000USD60,000USD98,000USD162,900,000USD6,760,000USD73,666,000USD84,498,000USD17,767,000USD
    Other Cashflows From Financing Activities-3,080,000USD79,346,000USD-3,087,000USD1,000USD608,000USD117,000USD117,000USD2,336,000USD
    Unclassified Investing Cash Flow1,535,000USD8,524,000USD1,438,000USD——-2,942,000USD-180,482,000USD—
    Unclassified Financing Cash Flow2,506,000USD31,237,000USD75,895,000USD—120,437,000USD—31,061,000USD85,654,000USD
    Issuance Of Capital Stock—110,237,000USD72,808,000USD73,501,000USD121,045,000USD35,000,000USD6,611,000USD87,990,000USD
    Unclassified Operating Cash Flow—-1,795,000USD—————-21,278,000USD
    Change To Liabilities———11,788,000USD2,076,000USD-4,601,000USD-6,219,000USD9,650,000USD
    Cash And Cash Equivalents Changes———6,080,000USD-9,124,000USD-16,537,000USD-40,938,000USD34,342,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductExemplar237,000USD0001356090-26-000017
    Q1 2026Quarterly · 2026-03-31ProductPapzimeos21,591,000USD0001356090-26-000017
    Q1 2026Quarterly · 2026-03-31ProductServices1,424,000USD0001356090-26-000017
    Q2 2025Quarterly · 2025-06-30ProductOther34,000USD0001356090-25-000024
    Q2 2025Quarterly · 2025-06-30ProductProduct41,000USD0001356090-25-000024
    Q2 2025Quarterly · 2025-06-30ProductServices781,000USD0001356090-25-000024
    Q1 2025Quarterly · 2025-03-31ProductOther23,000USD0001356090-25-000019
    Q1 2025Quarterly · 2025-03-31ProductProduct203,000USD0001356090-25-000019
    Q1 2025Quarterly · 2025-03-31ProductServices1,115,000USD0001356090-25-000019
    Q4 2024Quarterly · 2024-12-31ProductOther11,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductProduct187,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductServices992,000USDLegacy provider
    FY 2024Yearly · 2024-12-31ProductPapzimeos0USD0001356090-26-000009
    FY 2024Yearly · 2024-12-31ProductProduct Exemplar422,000USD0001356090-26-000009
    FY 2024Yearly · 2024-12-31ProductService Exemplar3,503,000USD0001356090-26-000009
    FY 2024Yearly · 2024-12-31SegmentBiopharmaceuticals0USD0001356090-25-000007
    FY 2024Yearly · 2024-12-31SegmentExemplar3,925,000USD0001356090-25-000007
    Q3 2024Quarterly · 2024-09-30ProductOther1,000USD0001356090-25-000034
    Q3 2024Quarterly · 2024-09-30ProductProduct66,000USD0001356090-25-000034
    Q3 2024Quarterly · 2024-09-30ProductServices886,000USD0001356090-25-000034
    Q2 2024Quarterly · 2024-06-30ProductOther13,000USD0001356090-25-000024
    Q2 2024Quarterly · 2024-06-30ProductProduct31,000USD0001356090-25-000024
    Q2 2024Quarterly · 2024-06-30ProductServices673,000USD0001356090-25-000024
    Q1 2024Quarterly · 2024-03-31ProductOther8,000USD0001356090-25-000019
    Q1 2024Quarterly · 2024-03-31ProductProduct138,000USD0001356090-25-000019
    Q1 2024Quarterly · 2024-03-31ProductServices919,000USD0001356090-25-000019
    Q4 2023Quarterly · 2023-12-31ProductOther78,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductProduct110,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductServices1,040,000USDLegacy provider
    FY 2023Yearly · 2023-12-31ProductOther84,000USD0001356090-25-000007
    FY 2023Yearly · 2023-12-31ProductProduct840,000USD0001356090-25-000007
    FY 2023Yearly · 2023-12-31ProductServices5,301,000USD0001356090-25-000007
    FY 2023Yearly · 2023-12-31SegmentBiopharmaceuticals75,000USD0001356090-25-000007
    FY 2023Yearly · 2023-12-31SegmentExemplar6,150,000USD0001356090-25-000007
    Q3 2023Quarterly · 2023-09-30SegmentBiopharmaceuticals0USD0001356090-23-000017
    Q3 2023Quarterly · 2023-09-30SegmentExemplar1,379,000USD0001356090-23-000017
    Q2 2023Quarterly · 2023-06-30SegmentBiopharmaceuticals0USD0001356090-23-000013
    Q2 2023Quarterly · 2023-06-30SegmentExemplar1,767,000USD0001356090-23-000013
    FY 2022Yearly · 2022-12-31ProductOther2,564,000USD0001356090-25-000007
    FY 2022Yearly · 2022-12-31ProductProduct1,903,000USD0001356090-25-000007
    FY 2022Yearly · 2022-12-31ProductServices10,094,000USD0001356090-25-000007
    FY 2022Yearly · 2022-12-31SegmentBiopharmaceuticals14,894,000USD0001356090-25-000007
    FY 2022Yearly · 2022-12-31SegmentExemplar12,015,000USD0001356090-25-000007
    Q4 2022Quarterly · 2022-12-31SegmentBiopharmaceuticals116,000USDLegacy provider
    Q4 2022Quarterly · 2022-12-31SegmentExemplar1,647,000USDLegacy provider
    Q3 2022Quarterly · 2022-09-30SegmentBiopharmaceuticals14,624,000USD0001356090-23-000017
    Q3 2022Quarterly · 2022-09-30SegmentExemplar2,098,000USD0001356090-23-000017
    Q2 2022Quarterly · 2022-06-30SegmentBiopharmaceuticals70,000USD0001356090-23-000013
    Q2 2022Quarterly · 2022-06-30SegmentExemplar2,841,000USD0001356090-23-000013
    Q1 2022Quarterly · 2022-03-31SegmentBiopharmaceuticals84,000USD0001356090-23-000009
    Q1 2022Quarterly · 2022-03-31SegmentExemplar5,429,000USD0001356090-23-000009
    FY 2021Yearly · 2021-12-31ProductOther1,008,000USD0001356090-24-000007
    FY 2021Yearly · 2021-12-31ProductProduct2,164,000USD0001356090-24-000007
    FY 2021Yearly · 2021-12-31ProductServices11,095,000USD0001356090-24-000007
    FY 2021Yearly · 2021-12-31SegmentBiopharmaceuticals922,000USD0001356090-24-000007
    FY 2021Yearly · 2021-12-31SegmentExemplar13,345,000USD0001356090-24-000007
    Q4 2021Quarterly · 2021-12-31SegmentBiopharmaceuticals199,000USDLegacy provider
    Q4 2021Quarterly · 2021-12-31SegmentExemplar3,485,000USDLegacy provider
    Q4 2021Quarterly · 2021-12-31SegmentTrans Ova20,537,000USDLegacy provider
    Q3 2021Quarterly · 2021-09-30SegmentBiopharmaceuticals129,000USD0001356090-22-000013
    Q3 2021Quarterly · 2021-09-30SegmentExemplar3,204,000USD0001356090-22-000013
    FY 2020Yearly · 2020-12-31SegmentBiopharmaceuticals21,780,000USD0001356090-23-000004
    FY 2020Yearly · 2020-12-31SegmentExemplar10,158,000USD0001356090-23-000004
    FY 2019Yearly · 2019-12-31ProductOther11,179,000USD0001356090-22-000002
    FY 2019Yearly · 2019-12-31ProductProduct23,780,000USD0001356090-22-000002
    FY 2019Yearly · 2019-12-31ProductServices51,803,000USD0001356090-22-000002
    FY 2019Yearly · 2019-12-31SegmentActo Bio-364,000USD0001356090-21-000003
    FY 2019Yearly · 2019-12-31SegmentAll Other Segments12,514,000USD0001356090-21-000003
    FY 2019Yearly · 2019-12-31SegmentHuman Biotherapeutics3,713,000USD0001356090-21-000003
    FY 2019Yearly · 2019-12-31SegmentPGENTherapeutics2,227,000USD0001356090-21-000003
    FY 2019Yearly · 2019-12-31SegmentTrans Ova68,672,000USD0001356090-21-000003
    FY 2018Yearly · 2018-12-31ProductCollaborationandlicensingagreements69,540,000USD0001628280-20-002699
    FY 2018Yearly · 2018-12-31ProductOther733,000USD0001628280-20-002699
    FY 2018Yearly · 2018-12-31ProductProduct28,486,000USD0001628280-20-002699
    FY 2018Yearly · 2018-12-31ProductServices52,419,000USD0001628280-20-002699
    FY 2018Yearly · 2018-12-31SegmentActo Bio6,684,000USD0001356090-21-000003
    FY 2018Yearly · 2018-12-31SegmentAll Other Segments30,213,000USD0001356090-21-000003
    FY 2018Yearly · 2018-12-31SegmentHuman Biotherapeutics0USD0001356090-21-000003
    FY 2018Yearly · 2018-12-31SegmentPGENTherapeutics29,021,000USD0001356090-21-000003
    FY 2018Yearly · 2018-12-31SegmentTrans Ova75,178,000USD0001356090-21-000003
    FY 2017Yearly · 2017-12-31ProductCollaborationandlicensingagreements134,624,000USD0001628280-20-002699
    FY 2017Yearly · 2017-12-31ProductOther643,000USD0001628280-20-002699
    FY 2017Yearly · 2017-12-31ProductProduct33,585,000USD0001628280-20-002699
    FY 2017Yearly · 2017-12-31ProductServices50,611,000USD0001628280-20-002699
    FY 2017Yearly · 2017-12-31SegmentActo Bio12,929,000USD0001628280-20-002699
    FY 2017Yearly · 2017-12-31SegmentAll Other Segments59,174,000USD0001628280-20-002699
    FY 2017Yearly · 2017-12-31SegmentMethane Bioconversion Platform14,336,000USD0001628280-20-002699
    FY 2017Yearly · 2017-12-31SegmentPrecigen53,184,000USD0001628280-20-002699
    FY 2017Yearly · 2017-12-31SegmentTrans Ova79,783,000USD0001628280-20-002699
    FY 2016Yearly · 2016-12-31ProductCollaborationandlicensingagreements109,871,000USD0001356090-19-000004
    FY 2016Yearly · 2016-12-31ProductOther1,048,000USD0001356090-19-000004
    FY 2016Yearly · 2016-12-31ProductProduct36,958,000USD0001356090-19-000004
    FY 2016Yearly · 2016-12-31ProductServices43,049,000USD0001356090-19-000004

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.